Published Date: 08 Mar 2023
A groundbreaking study by the University of Bristol and the University of Essex has revealed new insights into the importance of early childhood for lung health.
Read Full NewsIn a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?
New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.
A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.
A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.
1.
Eltrombopag Improves Outcomes in Kids With Newly Diagnosed ITP
2.
It Is Cancer in Kate Middleton.
3.
For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.
4.
Research finds COVID-19 mRNA vaccine sparks immune response to fight cancer
5.
How the metastasis of cancer is driven by cellular plasticity.
1.
The Benefits of Understanding Haptoglobin High: What You Need to Know
2.
Understanding Odontogenic Keratocyst: Symptoms, Causes, and Treatments from Dental Experts
3.
Unleashing the Power of AI: A Systematic Review of Predictive Biomarker Discovery in Immuno-Oncology
4.
Understanding Fibrosarcoma: What You Need to Know
5.
What is Hemorrhagic Cystitis and How to Manage its Symptoms
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
2.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
4.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
5.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation